Inspection delay yields ops duplication; Angel finds the right deal in England;

> Anika Therapeutics faces four months of operating duplicate facilities in Massachusetts, result of a delayed FDA inspection prior to equipment relocation. Anika release

> CMO Angel Biotechnology says it's close to finalizing a deal to expand its manufacturing base into England because it was unable to find the "right deal" in Scotland. Article

> Saudi Arabia's Shamla Pharmaceutical Industries, a partnership of three pharma companies has signed a deal to build a pharmaceutical factory at the Industrial Valley in King Abdullah Economic City. Story

> BioMarin Pharmaceutical is doubling its production capacity for both drug and trial-supply compounds. Article

> Drug sampling data gathered by Roger Bate at the American Enterprise Institute show that China is largely responsible for the fakes attributed to India. Story

> Baxter says short-term manufacturing delays have caused a shortage of premix nitroglycerin in dextrose. FDA drug shortage Listing

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.